ChromaDex Co. (NASDAQ:CDXC) Short Interest Up 8.5% in September

ChromaDex Co. (NASDAQ:CDXC) was the target of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 3,200,000 shares, a growth of 8.5% from the September 15th total of 2,950,000 shares. Currently, 6.7% of the shares of the company are sold short. Based on an average daily trading volume, of 278,300 shares, the short-interest ratio is currently 11.5 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of ChromaDex in a research note on Friday, August 9th.

Insider Buying and Selling at ChromaDex

In related news, Director Kristin Patrick sold 23,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $3.57, for a total transaction of $82,110.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 9.64% of the company’s stock.

Institutional Trading of ChromaDex

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Miracle Mile Advisors LLC purchased a new position in shares of ChromaDex during the 2nd quarter valued at approximately $27,000. The Manufacturers Life Insurance Company purchased a new stake in ChromaDex in the 2nd quarter worth $31,000. Merriman Wealth Management LLC acquired a new position in ChromaDex during the second quarter worth $32,000. Lazard Asset Management LLC purchased a new position in ChromaDex during the first quarter valued at $43,000. Finally, SG Americas Securities LLC purchased a new position in ChromaDex during the first quarter valued at $54,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

ChromaDex Stock Performance

Shares of ChromaDex stock traded down $0.12 on Thursday, hitting $3.44. The company’s stock had a trading volume of 195,441 shares, compared to its average volume of 302,159. The company has a market capitalization of $259.85 million, a price-to-earnings ratio of -71.20 and a beta of 1.86. ChromaDex has a 1 year low of $1.25 and a 1 year high of $4.65. The firm has a fifty day moving average price of $3.40 and a 200-day moving average price of $3.25.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.